Certaines complications peuvent être réversibles avec un traitement approprié.
RéversibilitéTraitement approprié
#3
Comment les complications affectent-elles la qualité de vie ?
Les complications peuvent gravement affecter la qualité de vie et nécessiter un soutien.
Qualité de vieSoutien médical
#4
Y a-t-il des risques de maladies associées ?
Oui, des maladies métaboliques ou neurologiques peuvent être associées à cette déficience.
Maladies associéesDéficience enzymatique
#5
Comment prévenir les complications ?
Un suivi médical régulier et un traitement précoce peuvent aider à prévenir les complications.
Prévention des complicationsSuivi médical
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour cette déficience ?
Les antécédents familiaux et certaines mutations génétiques augmentent le risque.
Antécédents familiauxMutations génétiques
#2
L'environnement joue-t-il un rôle ?
Des facteurs environnementaux peuvent influencer l'expression des gènes liés à l'enzyme.
Facteurs environnementauxExpression génétique
#3
Les maladies métaboliques augmentent-elles le risque ?
Oui, certaines maladies métaboliques peuvent prédisposer à des déficiences enzymatiques.
Maladies métaboliquesDéficiences enzymatiques
#4
Y a-t-il des groupes à risque particulier ?
Les personnes avec des antécédents familiaux de troubles lipidiques sont à risque.
Groupes à risqueTroubles lipidiques
#5
Comment le mode de vie influence-t-il le risque ?
Un mode de vie malsain peut exacerber les symptômes et augmenter le risque de complications.
Mode de vieRisque de complications
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase : Questions médicales les plus fréquentes",
"headline": "CDPdiacylglycerol-serine O-phosphatidyltransferase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les CDPdiacylglycerol-serine O-phosphatidyltransferase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Transferases (other substituted phosphate groups)",
"url": "https://questionsmedicales.fr/mesh/D017855",
"about": {
"@type": "MedicalCondition",
"name": "Transferases (other substituted phosphate groups)",
"code": {
"@type": "MedicalCode",
"code": "D017855",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.900"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase",
"alternateName": "CDPdiacylglycerol-Serine O-Phosphatidyltransferase",
"code": {
"@type": "MedicalCode",
"code": "D010717",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Manikandan Velayutham",
"url": "https://questionsmedicales.fr/author/Manikandan%20Velayutham",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India."
}
},
{
"@type": "Person",
"name": "Jesu Arockiaraj",
"url": "https://questionsmedicales.fr/author/Jesu%20Arockiaraj",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India. jesuaraj@hotmail.com."
}
},
{
"@type": "Person",
"name": "Vahab Ali",
"url": "https://questionsmedicales.fr/author/Vahab%20Ali",
"affiliation": {
"@type": "Organization",
"name": "d Laboratory of Molecular Biochemistry and Cell Biology, Department of Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna 800007, India."
}
},
{
"@type": "Person",
"name": "Kuljit Singh",
"url": "https://questionsmedicales.fr/author/Kuljit%20Singh",
"affiliation": {
"@type": "Organization",
"name": "d Laboratory of Molecular Biochemistry and Cell Biology, Department of Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna 800007, India."
}
},
{
"@type": "Person",
"name": "Ravin Seepersaud",
"url": "https://questionsmedicales.fr/author/Ravin%20Seepersaud",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Division of Infectious Diseases, San Francisco Veteran Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, California, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "COVID and depression among stratified population groups: a narrative review.",
"datePublished": "2023-08-03",
"url": "https://questionsmedicales.fr/article/37537632",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01213-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Willingness to Pay for HIV Prevention Commodities Among Key Population Groups in Nigeria.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36316139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.9745/GHSP-D-21-00303"
}
},
{
"@type": "ScholarlyArticle",
"name": "Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35718592",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.vaccine.2022.05.067"
}
},
{
"@type": "ScholarlyArticle",
"name": "Short-term air pollution exposure and mortality in Brazil: Investigating the susceptible population groups.",
"datePublished": "2023-10-23",
"url": "https://questionsmedicales.fr/article/37879554",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.envpol.2023.122797"
}
},
{
"@type": "ScholarlyArticle",
"name": "Leveraging information between multiple population groups and traits improves fine-mapping resolution.",
"datePublished": "2023-11-10",
"url": "https://questionsmedicales.fr/article/37949886",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-023-43159-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Transferases (other substituted phosphate groups)",
"item": "https://questionsmedicales.fr/mesh/D017855"
},
{
"@type": "ListItem",
"position": 7,
"name": "CDPdiacylglycerol-serine O-phosphatidyltransferase",
"item": "https://questionsmedicales.fr/mesh/D010717"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : CDPdiacylglycerol-serine O-phosphatidyltransferase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Comment diagnostiquer une déficience en CDPdiacylglycerol-serine O-phosphatidyltransferase ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nY a-t-il des biomarqueurs associés à cette enzyme ?\nQuels symptômes peuvent alerter sur un problème enzymatique ?\nPeut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Quels sont les symptômes d'une déficience en cette enzyme ?\nY a-t-il des signes cliniques spécifiques ?\nLes symptômes varient-ils selon l'âge ?\nDes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Peut-on prévenir les déficiences enzymatiques ?\nY a-t-il des conseils diététiques pour prévenir des problèmes ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nDes programmes de sensibilisation existent-ils ?\nComment le suivi médical contribue-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Quels traitements sont disponibles pour cette déficience ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques existent-ils ?\nComment la nutrition influence-t-elle le traitement ?\nY a-t-il des traitements expérimentaux en cours ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Quelles complications peuvent survenir ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de maladies associées ?\nComment prévenir les complications ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur CDPdiacylglycerol-serine O-phosphatidyltransferase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nL'environnement joue-t-il un rôle ?\nLes maladies métaboliques augmentent-elles le risque ?\nY a-t-il des groupes à risque particulier ?\nComment le mode de vie influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D010717?mesh_terms=Population+Groups#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en CDPdiacylglycerol-serine O-phosphatidyltransferase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests enzymatiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons cellulaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs lipidiques peuvent indiquer une dysfonction de l'enzyme."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter sur un problème enzymatique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques ou des anomalies dans la composition lipidique peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des anomalies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à visualiser des complications, mais n'est pas spécifique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en cette enzyme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques et des anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des troubles de la croissance ou des problèmes de reproduction peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge du patient."
}
},
{
"@type": "Question",
"name": "Des symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent ressembler à ceux d'autres troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si non traités."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences enzymatiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer la condition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour prévenir des problèmes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en acides gras essentiels peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les porteurs et aider à la planification familiale."
}
},
{
"@type": "Question",
"name": "Des programmes de sensibilisation existent-ils ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes éducatifs peuvent sensibiliser aux troubles métaboliques héréditaires."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical contribue-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de détecter précocement les anomalies et d'ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour cette déficience ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments lipidiques et une thérapie diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques existent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques approuvés pour cette condition."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adéquate peut aider à gérer les symptômes et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et métaboliques peuvent se développer si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent gravement affecter la qualité de vie et nécessiter un soutien."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies métaboliques ou neurologiques peuvent être associées à cette déficience."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement précoce peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux peuvent influencer l'expression des gènes liés à l'enzyme."
}
},
{
"@type": "Question",
"name": "Les maladies métaboliques augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies métaboliques peuvent prédisposer à des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque particulier ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents familiaux de troubles lipidiques sont à risque."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie malsain peut exacerber les symptômes et augmenter le risque de complications."
}
}
]
}
]
}
Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India. jesuaraj@hotmail.com.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
d Laboratory of Molecular Biochemistry and Cell Biology, Department of Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna 800007, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
d Laboratory of Molecular Biochemistry and Cell Biology, Department of Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna 800007, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Medicine, Division of Infectious Diseases, San Francisco Veteran Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, California, USA.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Medicine, Division of Infectious Diseases, San Francisco Veteran Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, California, USA.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Medicine, Division of Infectious Diseases, San Francisco Veteran Affairs Medical Center, and the Department of Medicine, University of California, San Francisco, California, USA. Electronic address: paul.sullam@ucsf.edu.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
Department of Chemistry, Interdisciplinary Institute of Indian System of Medicine, SRM Institute of Science and Technology, 603 203, Kattankulathur, Chennai, Tamil Nadu, India.
Publications dans "CDPdiacylglycerol-serine O-phosphatidyltransferase" :
The Covid-19 pandemic has impacted and infiltrated every aspect of our lives. Successive lockdowns, social distancing measures, and reduction in economic activity have developed a new way of living an...
Key population (KP) groups, such as female sex workers and men who have sex with men, in Nigeria rely on free HIV prevention commodities, including pre-exposure prophylaxis (PrEP) and HIV self-testing...
In 2020, we conducted a cross-sectional survey in 3 states with KP groups. The survey covered sociodemographic characteristics and willingness to use and pay for PrEP, HIVST, and condoms, and we used ...
Of the participants surveyed, 73% were willing to pay for PrEP services, 81% were willing to pay for HIVST, and 87% were willing to pay for condoms. Willingness to pay varied between the commodities a...
We demonstrate that KP groups are willing to pay for HIV prevention commodities, but there is a need to bridge the gap between the maximum amount they are willing to pay and retail prices. If prices a...
Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human i...
Statistical fine-mapping helps to pinpoint likely causal variants underlying genetic association signals. Its resolution can be improved by (i) leveraging information between traits; and (ii) exploiti...
Proper nutrition and a balanced diet are factors that influence the growth and development of children and adolescents, as well as body weight and health throughout life [...]....
Imatinib is used in gastrointestinal stromal tumours (GIST) and chronic myeloid leukaemia (CML). Oncology patients demonstrate altered physiology compared to healthy adults, e.g. reduced haematocrit, ...
This study utilised a previously validated a Chinese cancer population and assessed the impact of imatinib virtual-TDM in Chinese and Caucasian cancer populations across a dosing range from 200-800 mg...
Staged dose titration to 800 mg daily, resulted in recapitulation to within the target therapeutic range for 50 % (Chinese) and 42.1% (Caucasian) subjects possessing plasma concentration < 550 ng/mL w...
Virtual TDM highlights the benefit of pharmacokinetic modelling to optimising treatments in challenging oncology population groups....
Tailored obesity management includes understanding physical activity (PA) and its context, ideally in childhood before the onset of health risk. This cross-sectional study determined, by sex and popul...
The impact of social determinants on health status and outcomes has been widely established. However, it is recognized that health systems' ability to address community health needs may be limited. To...
The study employed a mixed-methods approach. We conducted a CHNA in the Galilee between November 2019 to January 2020 (n = 750). Additionally, we conducted focus groups using design thinking methodolo...
Galilee residents perceived sense of community (78%) as the major strength while cancer (53%) was perceived as the major health problem followed by heart disease and stroke (28.4%). The adjusted odds ...
CHNA can inform the design of tailored interventions that will improve health for Galilee residents addressing their socioeconomic-cultural-geographical characteristics. The study's findings raise the...
As the average age of first-time parents continues to rise, there has been a concerted effort by educators, policy makers and several reproductive health groups to improve fertility awareness. This st...